stoxline Quote Chart Rank Option Currency Glossary
  
ProKidney Corp. (PROK)
2.18  0.23 (11.79%)    04-17 16:00
Open: 1.99
High: 2.19
Volume: 1,379,527
  
Pre. Close: 1.95
Low: 1.98
Market Cap: 631(M)
Technical analysis
2026-04-17 5:16:21 PM
Short term     
Mid term     
Targets 6-month :  2.76 1-year :  3.23
Resists First :  2.36 Second :  2.76
Pivot price 1.86
Supports First :  1.86 Second :  1.55
MAs MA(5) :  2 MA(20) :  1.86
MA(100) :  2.14 MA(250) :  2.12
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  91.7 D(3) :  86.2
RSI RSI(14): 60.4
52-week High :  7.13 Low :  0.54
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PROK ] has closed Bollinger Bands are 1.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.19 - 2.21 2.21 - 2.22
Low: 1.95 - 1.97 1.97 - 1.98
Close: 2.16 - 2.18 2.18 - 2.2
Company Description

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Headline News

Fri, 17 Apr 2026
ProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy? - MarketBeat

Fri, 17 Apr 2026
Executive pay, governance on agenda at ProKidney (NASDAQ: PROK) vote - Stock Titan

Thu, 16 Apr 2026
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Mon, 13 Apr 2026
ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - Time to Buy? - MarketBeat

Tue, 31 Mar 2026
What Makes ProKidney Corp. (PROK) So Attractive - Yahoo Finance

Wed, 25 Mar 2026
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 142 (M)
Held by Insiders 9.367e+007 (%)
Held by Institutions 25.3 (%)
Shares Short 16,210 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.5843e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -20 %
Return on Assets (ttm) 306.2 %
Return on Equity (ttm) -26.6 %
Qtrly Rev. Growth 893000 %
Gross Profit (p.s.) 108.94
Sales Per Share -23.99
EBITDA (p.s.) 496111
Qtrly Earnings Growth -0.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -120 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.1
Price to Cash Flow -0.56
Stock Dividends
Dividend 0
Forward Dividend 1.533e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android